$13.60-0.35 (-2.51%)
News25/Ratings12
Price$13.60-0.18 (-1.27%)
04:00 PM07:45 PM
News · 26 weeks64-70%
2025-10-262026-04-19
Mix4590d
- Insider17(38%)
- Other11(24%)
- SEC Filings10(22%)
- Analyst7(16%)
Latest news
25 items- PRKorro Announces Oral and Poster Presentations at Upcoming Scientific ConferencesAmerican Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference3rd International Conference on Ureagenesis Defects and Allied ConditionsEuropean Association for the Study of the Liver (EASL) Congress 2026 CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) will take place at the following scientific confere
- SECSEC Form DEFA14A filed by Korro Bio Inc.DEFA14A - Korro Bio, Inc. (0001703647) (Filer)
- SECSEC Form DEF 14A filed by Korro Bio Inc.DEF 14A - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 15,000 shares of Korro's common stock at an exercise price of $13.46 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, April 8, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of
- INSIDERSEC Form 4 filed by Lynx1 Capital Management Lp4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lynx1 Capital Management Lp3 - Korro Bio, Inc. (0001703647) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)
- SECSEC Form EFFECT filed by Korro Bio Inc.EFFECT - Korro Bio, Inc. (0001703647) (Filer)
- SECSEC Form 424B5 filed by Korro Bio Inc.424B5 - Korro Bio, Inc. (0001703647) (Filer)
- SECSEC Form S-3 filed by Korro Bio Inc.S-3 - Korro Bio, Inc. (0001703647) (Filer)
- ANALYSTKorro Bio upgraded by Raymond James with a new price targetRaymond James upgraded Korro Bio from Mkt Perform to Outperform and set a new price target of $23.00
- INSIDERDirector Behbahani Ali was granted 207,100 shares (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Sandell Scott D bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner New Enterprise Associates 17, L.P. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Yang Rick bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Chang Carmen bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Florence Anthony A. Jr. bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Makhzoumi Mohamad bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Baskett Forest bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Walker Paul Edward bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERLarge owner Mathers Edward T bought $2,300,881 worth of shares (207,100 units at $11.11) (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- SECSEC Form 10-K filed by Korro Bio Inc.10-K - Korro Bio, Inc. (0001703647) (Filer)
- SECKorro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateNominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on Decem
- SECSEC Form SCHEDULE 13G filed by Korro Bio Inc.SCHEDULE 13G - Korro Bio, Inc. (0001703647) (Subject)